Experimental 'In-Situ' vaccine aims to train immune system against three cancers
NCT ID NCT03789097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs injected into a single tumor, plus an IV immunotherapy drug (pembrolizumab). The goal was to trigger the body's own defenses to attack cancer throughout the body, not just at the injection site.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a short course of immunotherapy and radiation shrink head and neck tumors before surgery?
- Can a Two-Drug attack shrink Hard-to-Treat head and neck tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New drug targets Hard-to-Treat breast cancer in advanced stage